Key Takeaways:

  • FDA issued 30 warning letters to telehealth companies for misleading marketing of compounded GLP-1 drugs as identical to FDA-approved versions
  • Enforcement targets companies claiming compounded semaglutide and tirzepatide are "the same" as Wegovy, Zepbound, and Ozempic
  • This represents part of broader FDA crackdown as agency moves to permanently end mass compounding of GLP-1 medications
  • If you're using compounded GLP-1s, your access may become limited as companies face regulatory pressure

FDA Escalates Enforcement Against Telehealth GLP-1 Marketing

The FDA delivered a significant blow to the compounded GLP-1 market in February and March 2026, issuing 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. The enforcement action specifically targeted companies that marketed compounded versions of semaglutide, tirzepatide, and liraglutide in ways that suggested equivalence with FDA-approved therapies.

"It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action," said FDA Commissioner Marty Makary. This represents a dramatic shift from the agency's previous approach to compounded GLP-1 oversight.

The warning letters follow a pattern of escalating FDA action. The agency's warning letter search shows that it has sent 88 letters about "false or misleading claims concerning compounded semaglutide and tirzepatide products" since September 2025. That's more enforcement letters than the FDA typically issues in an entire year for pharmaceutical marketing violations.

What Triggered the FDA's Crackdown

The enforcement action centers on telehealth firms that marketed compounded versions of semaglutide, tirzepatide and liraglutide products, in ways that suggested equivalence with FDA-approved therapies such as Wegovy, Ozempic, Mounjaro and Zepbound. In several instances, companies branded compounded medications under proprietary names that could imply FDA review or approval or used language that suggested therapeutic "sameness" with approved products.

The FDA's concern extends beyond marketing claims to real safety issues. As of Feb. 28, 2025, FDA has received more than 455 reports of adverse events with compounded semaglutide and more than 320 reports of adverse events with compounded tirzepatide. Many of these incidents involved dosing errors when people self-administered incorrect doses from multi-dose vials.

The quality control problems run deep throughout the compounded market. FDA import records and warning letters show that some compounders are ordering bulk ingredients from non-FDA-registered suppliers who could be selling anything. Independent quality testing of these mystery drugs is hindered by the lack of a U.S. Pharmacopeia reference standard for semaglutide and tirzepatide.

This creates a troubling scenario where you might think you're getting a safe, effective medication, but you could actually be injecting something with unknown potency, purity, or even identity. The lack of standardized testing means even well-intentioned compounders struggle to verify what they're actually dispensing.

The Broader Context: End of Compounded GLP-1 Era

These warning letters represent one front in the FDA's comprehensive effort to shut down the compounded GLP-1 market that flourished during drug shortages. On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances.

The proposed rule would permanently close the door on mass compounding, even if future shortages occur. The FDA is now inviting public comments through the docket by June 29, 2026, and will consider submitted comments before making a final determination.

Currently, both major GLP-1 drugs are no longer in shortage. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are no longer officially listed as in shortage. This means the legal justification for mass compounding has largely disappeared, leaving many telehealth providers in regulatory limbo.

For the most part, telehealth providers and compounding pharmacies have continued advertising and compounding products as patient-specific variants or copies of GLP-1 products. However, the regulatory landscape is shifting rapidly beneath their feet.

Novo Nordisk and Eli Lilly are actively filing suit and sending cease-and-desist letters to compounders, clinics, and telehealth companies, and multiple state boards of pharmacy are conducting investigations. Compounders that continue to produce these medications without robust documentation of medical necessity risk FDA enforcement actions, state regulatory discipline, and civil litigation from the branded manufacturers.

The warning letters sent to telehealth companies represent a relatively mild enforcement action. If such items are not addressed in a satisfactory or timely manner, the FDA has the authority to engage additional advisory action or, without further warning, initiate product recalls, product seizure, injunctions, and criminal actions, which could include civil monetary penalties.

For companies that built their business model around cheap compounded GLP-1s, this escalating enforcement creates an existential threat. Many may choose to exit the market rather than face potential legal costs and regulatory sanctions.

What This Means for You

If you're currently using compounded GLP-1 medications through a telehealth provider, this enforcement action signals that your access may become increasingly limited. The companies receiving warning letters must either change their marketing practices or risk further regulatory action that could shut down their operations entirely.

Your options for affordable GLP-1 treatment are evolving rapidly. While some telehealth providers may still offer legitimate compounded options under strict patient-specific criteria, the era of $150-300 monthly compounded GLP-1s is ending. Instead, consider exploring our comprehensive cost guide to understand branded medication programs, patient assistance programs, or work with providers who can help you find a clinic near you that offers transparent, compliant treatment options.

If you're concerned about the safety or legality of your current prescription, ask your provider whether their dispensing pharmacy publishes third-party batch testing results and operates under clear 503A or 503B classification. Legitimate providers should be able to explain exactly how their compounding practices comply with current FDA regulations.

Don't wait until your current provider faces enforcement action. Start exploring your backup options now, whether that's switching to FDA-approved medications through traditional healthcare channels or finding a compliant telehealth provider that can support your long-term treatment goals.

The regulatory crackdown may feel disruptive, but it ultimately protects you from potentially dangerous products while pushing the industry toward safer, more transparent practices. Your health outcomes are worth the effort to find a reliable, compliant provider.